Business Context and Reporting Period
Company: MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
Filing Type: Form 8-K (Current Report)
Date of Report: October 23, 2025
Reporting Period: Event-based report regarding clinical trial milestones.
Business Overview: MIRA is an emerging growth company developing Ketamir-2, a novel, non-scheduled oral analog of ketamine designed to treat neuropathic pain without the psychoactive effects associated with traditional ketamine.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical development progress.
Material Changes and Clinical Milestones
- Phase 1 Study Progress: Initiated the Multiple Ascending Dose (MAD) portion of the ongoing Phase 1 clinical trial for Ketamir-2 in healthy volunteers, following the completion of the Single Ascending Dose (SAD) phase.
- Safety Profile: To date, no serious or dose-limiting adverse events or clinically significant safety concerns have been reported in the SAD phase.
- Study Design: The MAD phase involves three cohorts of repeat daily oral dosing ranging from 150 mg to 600 mg for five days.
- Lead Indication Selection: Selected Chemotherapy-Induced Peripheral Neuropathy (CIPN) as the lead indication for the planned Phase 2a clinical evaluation.
Outlook, Management Commentary, and Risks
Management Commentary and Outlook
- Preclinical Efficacy: Preclinical studies indicate Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in reducing pain behaviors and restoring sensory function in neuropathic pain models.
- Market Opportunity: CIPN affects a large percentage of cancer patients with no currently FDA-approved therapies, representing a significant unmet medical need.
- Regulatory Strategy: The Company believes Ketamir-2 may qualify for FDA Fast Track designation due to the lack of approved treatments for CIPN.
- Drug Profile: Ketamir-2 is engineered for once-daily oral dosing with good absorption and without hallucinogenic or dissociative effects.
Risks and Contingencies
- Clinical Uncertainty: Future clinical results may not replicate preclinical efficacy or maintain the favorable safety profile observed in the SAD phase.
- Regulatory Approval: Fast Track designation is not guaranteed, and FDA approval for CIPN is not assured.
- Financial Constraints: As a clinical-stage company, the firm relies on capital markets for funding; the filing does not disclose current cash runway.
Investor Verification Checklist
- Verify the unblinded pharmacokinetic (PK) data and full safety results from the completed SAD phase.
- Confirm the enrollment status and timeline for the three MAD cohorts (150 mg to 600 mg).
- Review the Company's current cash position and capital raise plans to fund the upcoming Phase 2a trial.
- Assess the competitive landscape for CIPN treatments, including any late-stage competitors not mentioned in the filing.
- Monitor for official FDA communication regarding Fast Track designation status.